Summary: Bullish NVDA: CEO cites 5x ROI on AI infrastructure spend with everything sold out and demand described as incredible.

$NVDA CEO talks about demand and benefits of investment in #AI servers/infrastructure.
#SupDup $SMCI

One big question for Nvidia Corp. investors these days: Can artificial intelligence generate enough revenue to justify heavy past and future spending on graphics processing units and other AI hardware?

Chief Executive Jensen Huang must be getting this question a lot. He answered it on the company's earnings call in late August, but his response wasn't      enough to sway Wall Street, as Nvidia shares (NVDA) headed lower after the report. Huang took another crack at the topic at a Wednesday morning      Goldman Sachs event.

It's important to  understand where generative AI is in the cycle. Now, "infrastructure players like ourselves and all the cloud service providers put the    infrastructure in the cloud so that developers could use these machines to train the models, fine-tune the models, guardrail the models, so and so forth," Huang said.

You can't argue with the returns on investment for that, according to Huang.

'The return on that is fantastic because the demand is so great that ... every dollar that they spend with us translates to $5 worth of rentals. And that's happening, you know, all over the world, and everything is all sold out. And so the demand for this is just incredible.' #Nvidia CEO Jensen Huang.


Today's drop on European Patent News doesn't make any sense... they would be able to pay each shareholder $15/share cash or more given they have $20 mln cash on hand currently and could easily fetch more than $100 mln for their assets imo

Summary: Bullish ALLR at $1.45; argues drop is irrational, downside floored at $15/share liquidation value vs current price.

structural marker; pre-classified as canonical yfinance ticker

$ALLR $1.45 - Today's drop on European Patent News doesn't make any sense. Worst case unlikely scenario if the company sells its drug pipeline, shuts the doors (which will not happen at all), they would be able to pay each shareholder $15/share cash or more given they have $20 mln cash on hand currently and could easily fetch more than $100 mln for their assets imo
#SupDup


Summary: Author predicts CING and AVGR will be next to spike, following ATXI's 50%+ move.

$ATXI $3.50+ rn - UP 50+% within 3 weeks 🤑
Next to spike slowly will be $CING $5.75 and $AVGR $0.98 imo
#SupDup

https://t.co/vIeq7jjfBd

$ATXI $2.60 - Very LOW FLOAT stock with recent RS. Could it be the next one to take off? Possibly since most others similar ones have skyrocketted.
This one has more cash on hand than current market cap so their advance stage drug discovery pipeline is a bonus imo
#SupDup


Summary: Barclays maintains $693 price target on SMCI; author shares/adopts the bullish stance.

$SMCI - Super Micro Price Target Maintained With a $693.00/Share by Barclays


Summary: Long CING at ~$5, calling 100%+ spike; author already loading up.

Missed out on 300% to 400% rise in $LUNR? Don't worry, here's next one that will spike 100+% so your DD on Cingulate Inc. and if you like it start loading up $CING ~$5 like I have been.
I will continue to show plenty of other trade ideas that can reap you huge gains fast but only if you all engage and interact at least by hitting like or retweeting imo
#SupDup #FastMoney


Summary: SMCI below $23 is a golden buy for patient investors with 2-3 year horizon and high risk tolerance.

$SMCI <$23 = GOLDEN BUYING OPPORTUNITY for investors with 2-3 yrs patience and heavy risk tolerance imo.
#SupDup


Summary: Bearish LUNR: CEO selling 1.2M shares signals insider knows something negative about the company's prospects.

$LUNR $5.45 rn - Intuitive Machines Inc CEO Stephen Altemus Sells Over 1.2 Million Shares. Seriously?
He knows a lot about the company that we don't. For him to be dumping so much isn't good at this stage imo
#SupDup

https://t.co/Eb0QVhDecA


Summary: Recommends rotating into GNLX at $2 for gains down the road.

Bring some of your $LUNR $6 profits to $GNLX $2, you will be very happy down the road imo
#SupDup


Summary: Buying $100k SMCI under $27, 3-year hold expecting multi-bagger; either total loss or millions.

$SMCI - Going to buy 5 lots <$27 investing $100k with a plan to not look at stock price & forget for 3 yrs. Either I will lose $100k or make Million(s) of $. We shall see !
#SupDup


Summary: Long ALLR with $10 near-term floor and $25+ upside on Phase 2 anti-cancer drug Stenoparib results and sub-$2M valuation vs ~$20M cash.

$ALLR $1.40 - VALUEABLE & PROMISING asset that in Phase 2 trials Anti #CANCER drug Stenoparib showed clear clinical benefits, including TUMOR SHRINKAGE and long-term disease stability, in heavily pre-treated Ovarian cancer patients.
1.4 mln shares float, <$2 mln current valuation with ~$20 cash on hand rn. Stock should be at least $10 rn and could & will be $25+ someday imo.
#SupDup


Summary: Bullish GNPX, DRUG, and ALLR as short-squeeze candidates.

$GNPX & $DRUG = WORST NIGHTMARE for Short Sellers, next will be $ALLR imo
#SupDup


Summary: Bullish CING near-term; unusual accumulation hints at upcoming positive catalyst.

$CING - Someone knows something? Today's accumulation hints this to me.  I smell something good is cooking. Expecting good news in ST imo
#SupDup


Summary: Long ALLR to $10+; late-stage anti-cancer drug developer with $20M cash vs $2M market cap seen as deeply undervalued.

$ALLR $1.55 - Rarely will you ever find an advance stage Anti #Cancer drug developer co with $20 mln cash on hand that provides runway into 2026 having just $2 mln valuation.
This is why I see this stock rising to 10+ one day.
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Read  👇 fully and try to understand the huge future potential imo.
#SupDup
https://t.co/tDDdYEYf54


Summary: Favors KPRX among peers on cash position, low float/valuation, and buyout potential.

@wolverine2516 I like all 3 of them for different reasons but the strongest one could be $KPRX since it is more cash on hand, low float/valuation and huge future prospects for buyout imo

@SuperDuperInvst Which of the 3 is your favorite.


Summary: Buying RKLB around $6.50 for short-term/near-term trade.


Summary: Adding to VCIG position on dips for short-term and near-term hold.

$VCIG ~$0.14 -  Adding more on dips for ST & NT
#SupDup #Pennystock


Summary: Buying DECK below $155 as a short-term and near-term opportunity.

$DECK < $155 - Good opportunity to buy for ST & NT imo
#SupDup #Hoka #Deckers


Summary: Implied bullish on INTC; observes heavy accumulation at $19–$20 dips.

$INTC - Someone's loading up heavily lately between $19 - $20 on dips imo
#SupDup


Summary: Building long position in GNLX at $2.20, targeting 100–500% gains over 3 years.

$GNLX $2.20 - I am building a long position to sell at much higher prices in future. I expect 100% to 500% profits within next 3 years imo
#SupDup


Summary: Bought SMCI at $499 on Hindenburg-driven dip; regrets not sizing larger, implying bullish outlook.

$SMCI - Got a fill on a very small buy order at $499, thanks to Hindenburg - wish it was a larger size order.
#SupDup


Summary: Expects CING to rise 100%+ in the near/long term within the next few months from under $5.

I know I sounded like broken record when I kept posting about $LUNR $LUNRW and $VVOS here but within 2 months they are all up 100's of %.
Now I am gonna again sound like a paid pumper  😂  or broken record but DON'T missout on $CING <$5
It will see 100+% rise in NT & LT perhaps within next just next few months imo
#SupDup


Summary: Bullish on TNXP valuation but flagging cash constraints as a material risk.

@sxorpio7 @afonsobvalente Looks good to me at its current valuation but they are cash strapped which is a big concern imo

@SuperDuperInvst @afonsobvalente I meant $tnxp


Summary: Raising near-term PT to $5.75 and long-term PT to $9+ on VVOS.

$VVOS $2.40 - Raising my NT PT to $5.75 and LT PT to $9+ imo
#SupDup


Summary: Author's next pick is CING, implied to follow pattern of recent big gainers.

@wallstreetbets Forget $GME and $AMC - Check my picks have been skyrocketing $LUNR UP 300% $RKLB and next one will be $CING imo
#SupDup


Summary: Opening new long position in RKLB across day/swing/near-term timeframes.

$RKLB ~$6.15 - Starting a new long position for DT/ST/NT
#SupDup


Summary: Long GRI; holding position, not selling early — huge prospects from pipeline and 500+ proprietary compounds library.

$WGS $60 ($1.62 bln co valuation) - GeneDx Holdings Corp stock went up from <$1.20 to ~$62 within last 1 year, I was so bullish on this company about 3 years ago but real progress and stock rise came in recently. Checkout its stock price spike in last 10 months.
$GRI $0.70 (<$3 mln co valuation with $6 mln cash on hand) - Not going to make the same mistake of selling too early given the progress made so far and the huge prospects of their under development assets which can fundamentally change the way inflammatory, fibrotic and autoimmune diseases are treated.
Biggest hidden asset is their library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline imo.
#SupDup


Summary: Bullish CING: fresh capital removes cash concerns through Q3 2025, mgmt can focus on pipeline and potential licensing/buyout catalysts.

$CING - Now we don't have to worry about company's cash position for another almost a year and IF they get any licensing deal or buyout we will be GOLDEN. Mgmt can now fully focus on advancing the pipeline, regulatory work & seeking licensing deals rather  than worrying about and looking for money imo.

Cingulate raised approximately $12.5 million of capital in the third quarter of 2024. The capital raised provides the Company the cash runway to fund the clinical, manufacturing, and regulatory activities, as well as operating activities, into the third quarter of 2025, based on planned expenditures. Cingulate is targeting mid-2025 for the NDA submission of CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).


Summary: Expects COST to drop 5–10% post-earnings on potentially weak outlook despite decent results.

$COST $902.25 rn - #Costco ER should be decent but outlook could be weak, stock could see a drop of 5% to 10% post ER imo. Lets see !
#SupDup

---

ISSAQUAH, Wash., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today announced its operating results for the 16-week fourth quarter and the 52-week fiscal year ended September 1, 2024.

For the 16-week fourth quarter, the Company reported net sales of $78.2 billion, an increase of 1.0 percent compared to net sales of $77.4 billion in the 17-week fourth quarter of fiscal year 2023. For the 52-week fiscal year, the Company reported net sales of $249.6 billion, an increase of 5.0 percent from $237.7 billion reported in the 53-week fiscal year 2023.


Summary: Long SMCI; expects valuation to be significantly higher long-term.

@Mr_Derivatives Check my tweets on $SMCI today, you will see why its time to buy and not sell or short sell. Mark my words in LT the valuation of Super Micro will be way higher than what it is today imo

A word on Hindenburg.

When they release a short report. It’s typically too late to short.

Not saying to buy, but shorting into the hole, is dangerous.

Unless SMCI ends up like Enron, highly unlikely, I wouldn’t short here.

Just stay out.


Start loading up on $KPRX because in a few months you will be very happy imo

Summary: Load up on KPRX, CING, and ALLR for multi-month upside gains similar to LUNR's past run.

Missed out on $LUNR $3.30 to $11+ now & $LUNRW <$0.70 to $3.75 within a few months?

Start loading up on $KPRX $CING & $ALLR because in a few months you will be very happy imo
#SupDup


Start loading up on $CING because in a few months you will be very happy imo


Start loading up on $KPRX $CING & $ALLR because in a few months you will be very happy imo


Summary: Bullish CINGW warrants at $0.06 as leveraged play on CING upside over near and long term.

$CINGW $0.06 - Risky but might be cheap way to ride on $CING rise over NT & LT just like 100+% spike in $LUNRW since I showed as a risky but good buy imo
#SupDup


this stock could easily rise $100+ in a day on any good news. I still like this company's products that are in high demand imo

Summary: Bullish SMCI: heavy short covering due + $100+ upside possible on good news; likes products in high demand.

$SMCI $410 rn - I said it many times in the past that this stock will swing wildly in both directions. We have seen $100+ swings in a day many times in the past. Last 2 days have been mostly heavy short selling which eventually will need to be covered. If company doesn't have to or drastically reinstate their past earning, this stock could easily rise $100+ in a day on any good news. Lets see what $NVDA ER looks like later today. I still like this company's products that are in high demand imo
#SupDup


$CING $5.80 / ~$10 mln current valuation - Per mgmt: Cingulate currently has 2 product candidates...A 3rd product candidate CTX-2103 is being developed to serve roughly $5 billion US Anxiety market.

Summary: Bullish CING at $10M valuation vs $27B+ addressable ADHD+Anxiety market across 3 pipeline candidates.

$CING $5.80 / ~$10 mln current valuation - Per mgmt:
Cingulate currently has 2 product candidates. CTX-01 and CTX-02 that are being developed to serve the approximately $22.1 billion annual US ADHD maket.
A 3rd product candidate CTX-2103 is being developed to serve roughly $5 billion US Anxiety market.
#SupDup


I am adding heavily... this stock should be $10+ just based on its cash on hand

Summary: Heavily adding to ALLR at $1.60; targets $10+ based on cash position, clean cap structure, new leadership, and cash runway through 2026.

$ALLR $1.60 - I am adding heavily. Jumped to $2.25 bit ago and dipped suddenly. My guess is someone shorting heavily.
Not worried at all, taking advantage of lower price and buying more for ST, NT & LT because this stock should be $10+ just based on its cash on hand. It has clean slate, no toxic warrants or ATM offerings as stated by the mgmt. New dynamic leadership in place.
Cash that will last through 2026. Low float of 1.5 mln is going to make wild swings in both directions imo
#SupDup


$VCIG <$0.14 = Dangerously UNDERVALUED based on its fundamentals & prospects... makes it very attractive buy for penny stock lovers for NT & LT imo

Summary: Strong buy on VCIG at <$0.14: CEO raising stake, $10M buyback, $18M IPO pipeline, <$12M mktcap vs $25M+ sales at ~45% YoY growth.

$VCIG <$0.14 = Dangerously UNDERVALUED based on its fundamentals & prospects. CEO keeps increasing his stake now at 27%, $10 mln stock buy back announced, $18 mln potential IPO work news. Fastly growing & profitable company with current market cap of <$12 mln (Annual sales of $25+ mln with ~45% YoY growth rate) makes it very attractive buy for penny stock lovers for NT & LT imo
#SupDup


Summary: Long CING below $3.20, adding on dips; targets 100–1000% gain within ~1 year on licensing deal or buyout catalyst.

$CING <$3.20 - Started adding on dips to double my long position for NT & LT.
I am 99.99% sure this stock will rise 100% to 1000% in LT most likely within 1 year given we could hear about licensing deal or buyout given the huge $20 bln market opportunity for its pipeline drugs imo.
#SupDup


Summary: SMCI likely acquired within 2 years by NVDA, DELL, INTC, or AMD; bullish on price recovery.

@Tammy32607682 Most likely within next 2 yrs $SMCI $24 rn will get acquired by  $NVDA or $DELL or perhaps $INTC or $AMD imo
#SupDup

@SuperDuperInvst I hope it turns around 🤞


Summary: Shares analyst avg PT of $30.33 vs current $3.50, implying large upside.

$KPRX $3.50 rn - 3 Analysts avg PT $30.33  🤔
#SupDup

https://t.co/Pzdhp9DrEp


Summary: Long CING at sub-$5.75 with a plan to add on dips; expects slow rise to teens or higher long term.

@redrussunited If you are okay with risk and have LT hold/investment horizon yes $CING would be great investment at current <$5.75 price with a plan to add on dips. In LT this stock should be slowly rising to teens or higher imo
#SupDup

@SuperDuperInvst Long term. I am fine with high risk.

Would you say $CING ? Or is there anything else?


I like it now that they have started production in one of their PA factory. Power backup market is huge and if their clean Zinc based power storage product finds mass adoption...it could be great investment for LT imo

Summary: Bullish EOSE long-term on production start and large power-backup market opportunity; watching for a few quarters.

$EOSE $2.20 - From quick DD, I like it now that they have started production in one of their PA factory. Power backup market is huge and if their clean Zinc based power storage product finds mass adoption with homeowners, small & large businesses, industrial clients and others it could be great investment for LT imo
I will keep it on my watch list for few qtrs to see how their sales are and what's the p2p look like.
#SupDup

@SuperDuperInvst Hi Super- Stiefel came out with new 70 page report on EOSE over $9 price target- stock is up double digits percent today- any thoughts on a trade with EOSE


Summary: AVAV surging on ~$1B US Army contract win.

$AVAV - Drone maker Skyrockets on US Army contract of ~$1 bln
#SupDup


Summary: Adding to FSLR long on dips for short/near-term.

$FSLR ~$209 down $16+ rn so far this morning  WTH.
I am going to add more on dips for ST/NT
#SupDup


Summary: Still bullish on ALLR; wants to add more at lower prices.

@CDavidCJr Absolutely 100%
I want to add more so hoping it goes down bit more so I can grab at lower prices.


Summary: Adding to double a large long position in CING for near-term and long-term; strong buy conviction.

$CING ~$5.15 - WTH is selling when it is time to Buy Buy Buy imo.
I am adding more to double my large long position for NT & LT
#SupDup


Summary: Adding SMCI on dips; targets $650+ spike next week.

$SMCI $605 - $615 = Adding today on dips as I see spike to $650+ next week imo
#SupDup


Summary: Buying VCIG on dips and adding more; bullish on CEO stake increase to 27%+ and strong financials.

$VCIG $0.19 - CEO increases stake in co to 27+% per today's pr which is why I am buying on dips and plan to keep adding more for ST/NT & LT.
#SupDup

Prior to the transaction, Dato’ Victor Hoo beneficially owned and controlled 12.05% of the Company’s total outstanding shares, comprising 10.72% held directly and 1.33% of indirect shareholding through V Invesco Fund (L) Limited, a company he owns. Following the transaction, he now beneficially owns and controls a total of approximately 27.32% of the Company’s total outstanding shares. This represents an increase of 15.27% in his overall shareholding, underscoring his strong confidence in the Company’s strategic direction and future growth potential.

The CEO’s investment, combined with the impressive financial results for the first half of 2024, reflects VCIG’s strong growth prospects and commitment to long-term success. The Company reported notable financial metrics, including a 44% year-over-year increase in revenue, a 57% rise in gross profit, and a 25% growth in net income. These results are aligned with our full-year guidance of a 65% increase in revenue and 68% rise in gross profit for the financial year 2024, and may exceed these targets if current trends continue.


Summary: Buying HUMA at $5.25 for short-, near-, and long-term holds.

$HUMA $5.25 - Buying for ST, NT & LT
#SupDup


Summary: Buying VCIG dips again after locking quick profits on a spike; plans to rinse and repeat.

$VCIG $0.19 - Bought $0.19 - $0.225, Sold some on spike to $0.29 in pre market locking quick profits. Now again on dips buying back to rinse & repeat imo
#SupDup #PennyStock


I am VERY BULLISH for its LT prospects. I see the stock rising to $10+ some day

Summary: Very bullish ALLR long-term to $10+; thin float with tight hands means big news could trigger massive short covering.

$ALLR - I am VERY BULLISH for its LT prospects. At some point I may even double my long position because I see the stock rising to $10+ some day with many ups & downs. Any big good news will trigger massive short covering on this thin float stock with barely 1.4 mln shares many of which are in tight hands like me and many of you imo.
#SupDup


Starting to buy 1st lot batch out of the 5 lots with $100k investment to forget for 3 yrs hold period

Summary: Initiating long SMCI position, $100k across 5 lots, 3-year hold.

$SMCI <$25.90 now - Starting to buy 1 st lot batch out of the 5 lots with $100k investment to forget for 3 yrs hold period as I had stated before.
#SupDup


Summary: Long VCIG from ~$0.19 with near-term price target of $0.40–$0.75.


Summary: Tempted to short AMD after $7 spike off $148 low, for day/swing trade.

$AMD ~$155 - Low yesterday was $148 so with this $7 spike I am getting tempted to Short Sell for DT/ST imo
#SupDup


Summary: Buying heavily at $1.65–$1.70; expects ALLR to skyrocket.

$ALLR - Buying heavily at $1.65 - $1.70 as I see this could skyrocket like $GNPX imo
#SupDup


Summary: Shares Cantor Fitzgerald price target of $10 on LUNR; implied bullish.

$LUNR - Cantor Fitzgerald gives PT of $10
#SupDup


Summary: Buying dips in LUNR and BYON should return 10–20% within 1 week.

$LUNR and $BYON buyers on dips today should make 10% to 20% easily within 1 week imo
#SupDup


Summary: Bullish ALLR: thin float, cash well above market cap, sees upside similar to GNPX.

NEW PICK:
$ALLR 1.60 - Allarity Therapeutics, Inc. - Oncology / Ovarian #Cancer drug development pipeline.
Super Duper thin equity float of 1.4 mln shares.
Current co value ~$2.30 mln, Cash on hand ~$20 mln that provides runway into 2026. Paused use of ATM.
Do your DD. I feel it could possibly rise like $GNPX imo.
#SupDup


Summary: Bullish GNLX 100–500% over 3 years on cancer treatment pipeline per CEO thesis.

$GNLX $2.20 - Why this stock has potential to rise for sure between 100% to 500% within next 3 years. Listen to this CEO speech and you will see what this co is doing and its potential in hard to treat #Cancer treatments discovery imo
#SupDup

https://t.co/V2ctvX3TrQ


Summary: Celebrates RKLB gain from $6.15 to $22.25 and now loading up HOUR as a new long position.

$RKLB $22.25 rn  🤑 , Loading up $HOUR now
#SupDup @CathieDWood @BillAckman

https://t.co/5lyl7b3ZsZ

$RKLB ~$6.15 - Starting a new long position for DT/ST/NT
#SupDup


Summary: Buying CING on dips and planning to add more on further drops.

$CING $6 - I hope its not the capital raise coming, people with knowledge may be selling as seen from the large blocks on sell but irrespective I am buying more on dips with a plan to add even more in future should there be further drop imo
#SupDup


Summary: Buy FSLR under $207 on dips for short, near, and long term.

@wallstreetbets $FSLR <$207 on dips, time to BUY BUY BUY for ST, NT & LT imo

buying the dip once again https://t.co/OXikud5WOY


Summary: Bullish CING on quiet accumulation pattern; expects positive catalyst soon.

$CING - Someone knows something for sure, last 2 days slow & steady accumulation going on. Expecting some exciting news within next few days/weeks imo
#SupDup


Summary: After initial dip on earnings, NVDA will rise as strong demand and outlook are recognized; AI/data center demand here to stay.

Tomorrow as usual no matter what the earnings look like we will see wild swings in $NVDA. I believe initially stock will drop and then once people realize the demand is strong with projected outlook the stock will go up.  Irrespective of what anyone says, I firmly believe that #AI #LLM #ML #DataCenter #Computing #Storage demand is here to stay forever given all the technological applications & advancements happening in every sector globally imo
#SupDup


Summary: Bullish TSLA reaction to Q3 surprise profit and cheaper model announcement driving AH rally.

$TSLA - $20 rise in AHrs after ER that came in with surprise $2.17 bln profit for the 3rd Qtr. and announcement of plans for cheaper mass affordable model in 2025 imo
#SupDup #Tesla


Summary: Bullish CING: dilution fears overblown, data readout by year-end, and pending US ADHD licensing deal seen as major upside catalyst.

$CING $6.50 - Good news is not there won't be fear of dilution with capital raise since they already raised $10+ mln at I would assume between $6 - $10/share.
It only added max of 1.5 mln shares which is no big deal. Also the data read out will be by end of this year as stated by mgmt. When they sign US licensing deal for their lead ADHD drug we will be golden imo
#SupDup


Stock skyrockets in AHrs on strong earnings. Thanks to #AI. it is just the beginning for all the Chips, Servers and related infrastructure players

Summary: Broadly bullish on AI-driven chip, server, and infrastructure stocks as AI deployment cycle is just beginning.

$MU - Stock skyrockets 🚀in AHrs on strong earnings. Thanks to #AI. Told you all a month ago that AI is here to stay and it is just the beginning for all the Chips, Servers and related infrastructure players as more companies deploy  applications to enhance their products & services imo
#SupDup $SMCI $NVDA $AMD $DELL $HPQ $INTC $AMZN $TSLA $META $AAPL $IBM $GOOG
#SupDup


it is just the beginning for all the Chips, Servers and related infrastructure players


Summary: Expects positive catalyst for MBIO this week.

$MBIO - We should hear some good news this week imo
#SupDup


Summary: Surging AI cloud capex (up 55% in 2024, +40-42% in 2025) makes SMCI, DELL, NVDA, and VRT the big winners.

AI Cloud Spending Is Surging. What Stocks Are the Winners $SMCI $NVDA $DELL $VRT

Investors often get distracted by day-to-day stock volatility when they should be focused on long-term business fundamentals. The question to ask is what are the big buyers of technology doing in terms of budgets and spending plans?

The profit-reporting season for the June quarter      gave us a clear answer: Large technology companies are becoming more confident about their investments in artificial-intelligence infrastructure. They are increasing their spending.

Last month, Alphabet CEO Sundar Pichai told investors that his team analyzes every dollar spent on AI and that it was seeing "tremendous momentum" from those investments. Microsoft said demand for its Azure AI services was as high as it could handle and that it needed to buy more AI servers. Meta      Platforms' management also said they planned to "significantly increase" investments in AI infrastructure next year.

Susquehanna analyst Mehdi Hosseini raised his forecast for 2024 global capital expenditure spending by the 12 top cloud computing providers by 3% to $192 billion, which means spending would be 55% higher than in 2023. He  said spending from by the group will increase by another 40% to 42% in 2025.

Make no mistake. Those are eye-watering numbers. If they come to pass, the big winners will be AI server makers, including Super Micro Computer and Dell Technologies, suppliers of AI graphics processing units such as Nvidia, and companies that provide cooling and power equipment for data centers, including Vertiv Holdings.


suppliers of AI graphics processing units such as Nvidia


the big winners will be AI server makers, including Super Micro Computer and Dell Technologies


companies that provide cooling and power equipment for data centers, including Vertiv Holdings


Summary: Bought AMD at $157 for quick/day/swing trade; live long position.

$AMD - Bought at $157 for QT/DT/ST
#SupDup


Summary: Bullish SMCI on strong order book and improving margins; conditional NVDA beat should lift the sector.

@DanielM_W $SMCI is short sellers favorite right now but they are playing with fire given their order book is extremely strong and this qtr should be better with sales & margins. IF $NVDA beats and raises outlook, the sector should get a liftoff imo

@SuperDuperInvst Sold a little to add to SMCI :)


IF $NVDA beats and raises outlook, the sector should get a liftoff imo


Summary: Bought ASTS under $25 for a day/swing trade.


Summary: Bullish SMCI above $50 breakout; targets $52–$57 on continuation.

$SMCI $49.25 - Flirting with $50 for the 1st time in a long time, IF it breaks it then next stops $52 - $57 imo
#SupSup


Adding more this morning... $25+ ... a steal at current price for LT investors imo

Summary: Adding to KPRX under $3.70; $25+ target on $10M mkt cap vs $30M cash + $300M+ licensing deal and pipeline upside.

$KPRX <$3.70 - Adding more this morning. I wish I could not look at the stock price for 2-3 years and when I see the stock be at $25+  👀  😍
This one is a keeper for investors with patience & clear vision given current mkt cap of just $10 mln when cash on hand is ~$30 mln, $300+ mln strategic development & licensing deal in place for one of the pipeline drug, huge potential for other drug in the pipeline and much more makes this a steal at current price for LT investors imo.
#SupDup


Summary: Bought FSLR at ~$210.75 for day/swing/near-term trade.

$FSLR - Bought at ~$210.75 for DT/ST/NT
#SupDup


Summary: Bullish CING: expects stock to surge once a licensing partner is signed for their ADHD drug.

@ib55h $CING - At times mgmt wait till later to get the best deal possible. In case of Cingulate their data looks amazing so they may not be rushing yet. Who knows but whenever they get to sign a partner for licensing their ADHD drug, stock will go bananas imo

@SuperDuperInvst We are waiting for this in the third and final phase of clinical trials


Summary: Rotate into CING at $4.40; author sees upside from here.

Time to bring your $HUMA $5.25+ money to $CING $4.40 imo
#SupDup


Summary: Shorting ASTS into the spike at $38.75+.

$ASTS $38.75+, Starting to short sell again on spike
#SupDup

---

$ASTS - $37.25 now minutes later  🤑


Summary: Adding and holding KPRX, CING, ALLR long-term; valuations below cash on hand with strong drug pipelines vs MDGL's $5.6B cap for one approved drug.

$MDGL $260 - UP $44 after ER. Current market cap of $5.6+ billion  😍
Only has 1 FDA approved drug but look at the valuation.
After having seen many such Pharma companies valuation and comparing them to $KPRX $CING $ALLR and a few others drug pipeline, future potential & current low valuations lower than their cash on hands, I am going to add more and hold for LT imo.
#SupDup


Summary: Expects a short squeeze spike in CETX similar to recent spikes in comparable names; bearish on short sellers implies bullish on price.

Short Sellers are going to get fried in $CETX $0.31 just like they did with recent massive spikes in $GRI $DRUG $BIVI $GNPX & $ATNF imo
#SupDup


I am loading up. It can quickly rise to $1 - $3 in 2025 or sooner given currently the company is undervalued and that they plan to launch 2 new very exciting Quantum Resistant Chips this qtr.

Summary: Loading up LAES at $0.37; targets $1–$3 in 2025 on undervaluation and upcoming Quantum Resistant Chip launches.

$LAES $0.37 - I am loading up. Do your indepth DD and if you like it, Start LOADING UP all you penny stock lovers. It can quickly rise to $1 - $3 in 2025 or sooner given currently the company is undervalued and that they plan to launch 2 new very exciting Quantum Resistant Chips this qtr.
This company has products that are critical to #Crypto #Cyber #Security #AI #Semiconductor #Satellites #EV and many other sectors imo
#SupDup #PennyStock #PennyPick @ACInvestorBlog


Summary: Looking to short AMD at $150+ for a day/swing trade after bounce from $133.

$AMD - Getting tempted to short sell at $150+ from last week's dip to $133 for DT/ST imo
#SupDup


Summary: Long CING: sub-$20M valuation with $10M+ cash, late-stage pipeline and PTR tech make it an attractive buy with potential to replicate SMMT's run.

$SMMT Summit Therapeutics stock went from <$1.70 to ~$34 last week all within less than 1 yr making company's valuation spike to ~$25 bln  😍
$CING $5 can do the same too IF the management plays its card well because it has all or better ingredients comparatively. Current company valuation of under $20 mln with $10+ mln cash on hand makes the very attractive buy based on its late stage drug discovery pipeline and PTR technology for Time Release drug dosage for both ST, NT & LT imo
#SupDup


Summary: Long KPRX with LT PT $25+ from $3.60; bullish on Kiora Pharmaceuticals' retinal disease pipeline.

$KPRX $3.60 - DON'T missout on this one, Patience will pay off HUGE on this one imo. My LT PT is $25+
Check it out and see for yourself why I am so bullish  👀
#SupDup

https://t.co/7HxvTYEiTZ

New Stock Pick:
$KPRX $3.60 - Kiora Pharmaceuticals, Inc. progressing drug developments for Retinal Diseases to Slow, Stop or Restore lost Eye Vision  👀
Current Value: ~$10 mln, 3x Cash on hand of ~$30 mln (Expected runway into 2027)
Equity float: 1.36 mln shares
$300+ mln


Summary: Bullish reaction to Rocket Lab securing multi-launch Neutron contract with commercial satellite operator.

$RKLB - NEWS !!  🚀
Rocket Lab Signs Multi-Launch Contract for Neutron with Confidential      Commercial Satellite Constellation Operator.
#SupDup

https://t.co/JRud4WlMxC


Summary: Extremely high conviction long CING under $3.40, expecting 100%+ return within 1 year.

$CING <$3.40 - 99.9% chance stock will rise 100% or more within 1 year. Investors with patience in LT will make a boat load of money on this one imo
#SupDup


Summary: Actively buying CETX heavily at $0.29–$0.31.

$CETX - I am buying heavily right now $0.29 -$0.31
#SupDup


Summary: Prefers KPRX at $3.65 as the safer, better long-term pick.

@mike_newitt04 Tough call depends on many factors but if you have LT patience $KPRX $3.65 is more safer and better imo

@SuperDuperInvst If you had to only choose 1 of these which one you picking?


Summary: Bullish on SMCI: stock down 50%+ while sales/profits rising, deeply undervalued vs NVDA, though near-term pressure may persist.

Super Micro Computer Inc trades as SMCI on Nasdaq

@DanielM_W @ComeOnJuice Yes agreed. Stock has dropped from $1225 to $383 now all when their sales and profits are rising. Even if they inflated little bit of their sales, compared to Nvidia valuation this company is very undervalued. But in ST the stock price may remain under pressure imo

@ComeOnJuice @SuperDuperInvst There may be something to it but for the share price to have dropped 50% since the summer then a lot is priced in


Summary: Adding more CING on dips; bullish on sub-$20M market cap, $10M+ raise, FDA food effect study readout by EOY, and possible US licensing deal for ADHD drug.

$CING $5.90 rn - Mid August stock shot up to $20+
So why would those that bought $10+ mln of about 1.5 mln stocks at perhaps $6 - $10 or even $15/share would sell now under $6? Think current market cap is so low under $20 mln. Several NT catalysts including possible US licensing deal for their lead drug for ADHD imo. I will be adding more on dips for NT & LT imo
#SupDup

Per today's news:
On September 12, 2024, the Company announced that it had commenced its final FDA-required study, which is a food effect study, for CTx-301 (dexmethylphenidate) for the treatment of ADHD. A data readout from the study is expected by the end of 2024. Additionally, Cingulate has raised over $10 million in additional capital since the middle of August 2024 and has received notification from Nasdaq that it is now in compliance with Nasdaq listing requirements.


Summary: Tentative long ASTS for long-term investors at $17–$24; wait for earnings clarity before going in full force.

$ASTS $24.50 - I mentioned few weeks ago that it has unique technology which still needs to prove it will be effective. Secondly I want to see actual meaningful sales & clear path to profitability. I don't expect anything exciting in terms of #'s when they release their earnings. It is a capital intensive sector but if they succeed it could command high PE.  I would wait for a couple of quarters to get some color & clarity before going in full force. But if you are in for LT it may be not a bad time to start buying between $17 - $24 imo
#SupDup

@SuperDuperInvst What’s your current position in ASTS? Any expectations for price movement ahead of earnings?


Summary: SMCI heading to $500+ once broad market headwinds subside, based on relative strength at $462 despite DJIA/Nasdaq selling.

$SMCI $462 rn - UP $25+ so far this morning while #DJIA is  down 450 points #Nasdaq is down 300 points, what does this tell you? It means stock will be $500+ when Dow and Nasdaq are not down so much but when up that much imo
#SupDup


Summary: Scotiabank raises ASTS price target to $45.90 from $28.00; author shares/adopts bullish call.

$ASTS $32.55 - SpaceMobile Price Target Raised to $45.90/Share From $28.00 by Scotiabank  🤔


Summary: Buy CING before institutional discovery drives it higher.

$CING - Get in b4 the big players discover it imo
#SupDup


Summary: Bullish ALLR on impressive senior hires from Eli Lilly, Celgene, and Novo Nordisk to lead clinical and commercial development.

$ALLR - Recent new hires, VERY Impressive !
Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company’s clinical development programs

Eli Lilly and Celgene veteran Jose Iglesias, M.D., joins as Consultant Chief Medical Officer to drive the stenoparib program toward regulatory approval

Former President of Novo Nordisk’s U.S. Operations, Jesper Høiland, appointed as Strategic Advisor
to guide strategic initiatives and optimize commercial potential
#SupDup

https://t.co/1ghtjm8N0g


Summary: Expects LUNR and RKLB to continue as multi-bagger candidates alongside future picks.

Missed out on many of my long stock trade ideas that quickly went up 100% to 500%? Don't worry there is always tomorrow. I will find and show you another and many other stocks that can rise as fast or even faster than  🚀  $LUNR $RKLB
This is home to MULTI BAGGERS 💰  imo   🤑
#SupDup


Summary: Long SMCI; believes scare tactics are suppressing price and stock will be way higher long-term.

$SMCI - They stole and still stealing your shares cheaply by using scare tactic. Stock will be WAY HIGHER in LT imo
#SupDup


Summary: Bearish SMCI on delayed 10-K filing for FY2024.

$SMCI - NEWS !  Not good imo
Super Micro Computer, Inc. to Delay Form 10-K Filing for Fiscal Year 2024


Summary: Adding to long position in VCIG after AH price action.

$VCIG $0.20 - Adding more after seeing $0.27 in AHrs last evening.
#SupDup


Summary: Expects TSLA to rise to $275+ by end of year.

@FAYONAAA2 Hard to predict but should rise to $275+ imo

@SuperDuperInvst What this thought about TSLA end of year


Summary: Janney raises FSLR to Buy from Neutral with $260 PT; author shares/adopts the upgrade.

$FSLR - First Solar raised to Buy from Neutral, Price Target Announced at $260.00/Share by Janney Montgomery Scott
#SupDup


Summary: Aggressively adding SMCI ahead of 10:1 forward split on improving margins and strong product demand; expects strong gains post-split.

$SMCI $567 rn, those that dare this week and buy should reap strong gains post forward split of 1:10 in Oct. This is an early Christmas gift to be able to buy at such low prices this week.
I am adding aggressively because their margins are improving and have super duper demand for their products imo
#SupDup


Summary: Avoid DJT on fundamentals; only upside case is Trump winning presidency.

industry='Internet Content & Information'

@CICICHEN261822 Its a speculative play. Based on fundamentals I would avoid but if Trump becomes President you know it could skyrocket imo

@SuperDuperInvst hey,how do you think $DJT?


Current avg PT is $30.33/share Buy rating with $27 by Maxim Group Buy rating with $10 by HC Wainwright Buy rating with $54 by Ladenburg Thalmann

Summary: Shares three analyst Buy ratings on KPRX with an average PT of $30.33 vs $3.50 current price.

$KPRX $3.50 - Current avg PT is $30.33/share   😍
Buy rating with $27 by Maxim Group
Buy rating with $10 by HC Wainwright
Buy rating with $54 by Ladenburg Thalmann
#SupDup


Summary: Bearish ASTS: overvalued on current metrics, no analyst-expected profit for 3+ years.

@NoKnownHeir @izvalgos Point is that when I say it is OVERVALUED based on its current valuation and future prospects.
Check analyst estimates on it, you will see they don't expect profit for next 3 yrs imo

@izvalgos @SuperDuperInvst Comparing $ASTS to $AMC is like comparing a mule to an F16.


Summary: Short PLTR from ~$42.90, adding on spikes; ASTS called overvalued at $38+ and now trading at $23, validating the bearish thesis.

$PLTR - Short Sold ~$42.90 will add more on every spike.  Remember I had told you all about $ASTS that it was OVERVALUED at $38+, look now few weeks later it is at $23 same with $AMC back when it skyrocketed to $70+ and then it tanked at one point to under $0.50 ($4 rn on reverse split adjusted) imo
Click link below to see proof.
#SupDup

https://t.co/mYHrdEcXQp


OVERVALUED at $38+, look now few weeks later it is at $23


Summary: Adding to long GRI position on the dip from $2+.

$GRI $0.72 - Doubling my long position on dip from $2+
#SupDup


Summary: Bullish MBIO; expects $0.33–$0.37 after $0.30 break, with potential $0.50+ on positive news.

$MBIO  ⚡  break $0.30 next stops $0.33 - $0.37
Any good news next week we may even see $0.50+ imo
#SupDup


Summary: Still long VCIG and plans to add; CEO recently raised equity stake to 27%+.

@GylHwd96069 Stocks go up and down all the time. If there is any new news from the company I will share. I still own and plan on adding more after seeing its CEO having recently boosted his equity stake to 27+ now imo

@SuperDuperInvst Don't you have nothing to say about the $vcig legends?


Summary: Adding to ALLR position below $1.40 for short, near, and long-term holds.

$ALLR <$1.40 - Adding more on dips for ST, NT & LT
Thanks to whoever that is shorting or selling.
#SupDup


Summary: Bullish SMCI; expects a strong rise on any positive catalyst, possibly next week.

@WilliamMastell2 It can easily happen, if not next week some other time but I am sure it will rise strongly on any good news imo

@SuperDuperInvst Do you see SMCI pop $50+ next week?


Summary: Loading up on CETX at $0.31, citing tiny $95K mcap vs $65M revenue.

$CETX $0.31 - That's why I am loading up imo 😍  ⚡  🔥  🚀
#SupDup

@SuperDuperInvst $CETX  Mcap =  95K    on 65M revenu  !!  float is 240K


Summary: ATLX below $7.75 is a good buy for short-term and near-term.

industry='Other Industrial Metals & Mining'

$ATLX <$7.75 - Good buy for ST & NT imo
#SupDup


Summary: Bearish ASTS at ~$31: fundamentals don't support valuation, unproven tech, meaningful revenue years away — wait before buying.

$ASTS ~$31 - Be careful, Fundamentals don't support current valuation. This is a very speculative stock. Wait to see next 2 - 3 quarterly earnings to get a feel about its actual potential. It will take years before we will see meaningful sales or they could become profitable.  Technology still needs to be proven that their 140 Mbps data transfer via Satellites will work reliably. I have Gigabit broadband internet and it still is slow sometimes because actual data upload & download speeds are barely 150 Mbps to 300 Mbps imo
#SupDup


Summary: Calls for CEO replacements at INTC, TRIP, and SNAP due to failed leadership harming sales, profits, and shareholder value; implicitly bearish on current trajectories.

I repeat $INTC, $TRIP and $SNAP needs to fire their failed & useless CEOs and replace with smart leaders that knows how to grow sales & profits which can ultimately result in rising stockholder value imo
#SupDup #Intel #TripAdvisor #Snap #Snapchat


Summary: All three small biotechs have later-stage pipelines than recent $1.75B/$1.2B deal comps and should attract licensing or buyout interest.

$CING $KPRX $ALLR mgmt & investors take a note  👇
Few companies with Pre Clinical & Phase 1 status drugs recently managed to secure $1.75 bln & $1.2 bln value deals for Buyout/Licensing of Drug rights.  All 3 above mentioned companies have much more promising and later stage drugs in development so find company(s) interested in Licensing and/or Buyout imo.
#SupDup @CingulateInc @KioraPharma @AllarityTx

https://t.co/AmC7LQBWvP


Summary: Ascendiant Capital raises VVOS PT to $6.60 from $6.40; author shares/endorses the bullish target raise.

$VVOS $2.70 - Vivos Therapeutics Price Target Raised to $6.60/Share From $6.40 by  Ascendiant Capital


Summary: MRNA below $58 is an attractive buy near- and long-term on its diverse vaccine pipeline.

$MRNA <$58 is becoming attractive buy for NT & LT investors due to its strong diverse pipeline of variety of vaccines for many life threatening ailments imo
#SupDup


Summary: Bullish on CING, GNLX, and AVGR; expects each to spike on upcoming good news like ASTS did.

$ASTS $36+ rn, People buy when good news come out and chase it but the ones that make more money are those that load up when no one is interested. Yesterday or ealier it was <$28 and look at now.
Same will happen someday with $CING $GNLX $AVGR for example as they all are ripe for some good news  imo
#SupDup


Summary: Warns of likely dilutive capital raise ahead; implied bearish/cautious on GNPX.

$GNPX $2.25+, Be careful I have a feeling they will do a capital raise imo
#SupDup


Summary: Shares Rosenblatt's maintained $200 price target on NVDA; author adopts bullish stance.

$NVDA $125 - Nvidia Price Target Maintained With a $200.00/Share by Rosenblatt  😍
#SupDup


Summary: PLTR overvalued on fundamentals and near-term prospects at $33; warns against chasing S&P 500 inclusion news.

$PLTR $33 - I feel it is fully priced or even OVERVALUED currently based on its fundamentals and NT prospects. Be careful chasing it on S & P 500 addition news imo
#SupDup


Summary: Actively buying RKLB on dips for both short/near-term and long-term holds.

$LUNR $5+ rn, I have been buying $RKLB on dips for ST/NT & LT imo
#SupDup


Summary: Bearish on Ulta Beauty after earnings; results and outlook deemed ugly.

$ULTA - Ulta Beauty ER out, ugly results and outlook imo
#SupDup https://t.co/49pOJ02LFV


Summary: Long GNLX targeting 100–500% gain over 3 years on undervalued late-stage biopharma pipeline for hard-to-treat cancers with $40M+ cash runway.

🚨 NEW stock pick:
$GNLX $2.15 - Genelux Corp <$75 mln valuation rn.
Hot undervalued late stage biopharmaceutical company with diverse drug discovery pipeline of hard to treat #CANCER drugs (Oncolytic Immunotherapies). Sufficient cash on hand ($40+ mln) to last into 2026
I expect 100% to 500% rise within the next 3 years. Great NT & LT investment imo

Drug pipeline of Platinum Resistant/Refractory Ovarian Cancer, Small & Non Small Lung Cancer and other aggressive or difficult to treat Cancers.
Do your DD and if you like what you see, you know what to do.
#SupDup


Summary: Bullish CING at $5.15 as a buy across short, near, and long-term timeframes.

$CING $5.15 - Keep your 👀 on it, great ST, NT & LT buy imo
#SupDup


Summary: Shares/endorses Ascendiant Capital's Buy rating on Cingulate with $75 PT.

$CING $6.10 - Cingulate maintained at Buy,  PT of $75 by Ascendiant Capital  😍
#SupDup


Summary: Author expects patience to pay off hugely on recent picks CING, ALLR, and KPRX, analogizing to WGS's 8000%+ run.

$WGS (used to be $SMFR I showed to my followers) ~$1 to $85+ run within a year went UP 8000+%.
Patience will payoff huge for few of my recent picks imo:
$CING $4.30
$ALLR $1.55
$KPRX $3.70
#SupDup

https://t.co/XdiiQQLWjA

$CMLF is now $SMFR. Merger with Sema4 happened.
In somewhat similar sector as $ILMN imo.
#SupDup

https://t.co/EOoqWn7YZ3


Patience will payoff huge for few of my recent picks imo: $ALLR $1.55


Patience will payoff huge for few of my recent picks imo: $KPRX $3.70


Summary: Bullish SMCI; views Hindenburg short report as a buying opportunity, expects price to recover quickly before NVDA earnings.

Thanks for creating a great opportunity to buy $SMCI cheaper so far this morning.
Cover quickly before $NVDA ER tomorrow and lock your profits from your scare tactic game. What happened to Adani Enterprises? Have you seen its valuation now? Check it out, it did NOTHING all your allegations were baseless as so far todate India's SEBI hasn't taken any actions against Adani mgmt but they have been coming after you guys for illegal manipulation imo

NEW FROM US:

Super Micro—Fresh Evidence Of Accounting Manipulation, Sibling Self-Dealing And Sanctions Evasion At This AI High Flyer

https://t.co/TaWfYbJVUA $SMCI

(1/x)


Summary: Bullish SMCI; dismisses short-seller concerns as fluff, business growing as usual.

They have not been quiet, they already released statements saying there will be no material changes to the to be lately filed 10k. Short sellers always come up with old outdated stuff and most of it is fluff scare tactic although it may have few things that may be true.
Business is growing and as usual imo

@SuperDuperInvst OR Accounting manipulation by SMCI. Company has been very suspiciously quiet imo.
Dell getting hammered too.


Summary: Bought more ASTS for day/swing trade, exploiting large daily swings.

$ASTS ~$24 - Bought more for DT/ST.
I love the daily $2 to $4 swings in both directions. Helps trading so much easier to make $ imo
#SupDup


Summary: Bullish CING as a cheap M&A target for major pharma players.

$CING $5.85 - VERY ATTRACTIVE takeover candidate at dirt cheap valuation for a large multinational Pharma giant like Pfizer, Merck, Johnson & Johnson, Novartis, Roche, Sanofi, Astra Zeneca, Bristol Myers Squibb, Amgen, Eli Lilly, Ranbaxy Labs, Abbott, Sun Pharma, Boeringer Ingelheim, GSK, Cipla or Teva Pharma imo
#SupDup


Summary: Actively adding to VCIG at $0.195, expects a run from $0.25 to $0.75.

$VCIG $0.195 - I am adding slowly & steadily.
Some day run from $0.25 to $0.75 will be like  🔥  🚀 just like how today we saw $LUNR jump to $6+ from $4 in a day imo
#SupDup


Summary: Loading up on ATLX under $7.75 as a lithium play for short and near term.

$ATLX <$7.75 - Lithium play.  I am loading up for ST & NT
$TSLA ~$358 rn, UP $36+ today so far  🔥  UP 115 since Trump victory news imo.
#SupDup


Summary: Bullish SMCI as a long-term buy-on-dip opportunity, analogizing to Adani post-Hindenburg recovery.

$GS - Goldman Sachs had invested heavily in India based Adani group stocks on dips after Hindenburg report. If I am not wrong they had bought $2 bln of stocks and with rise they within a year or so have tripled their investment. Could they or someone like Warren Buffett be loading up $SMCI today on dips?  Great opportunity for LT investors with 2-3 yrs holding patience imo
#SupDup


Summary: Long KPRX with LT price target of $25+ from under $4, citing potential institutional discovery in small-cap biotech.

$KPRX <$4 rn - My LT PT is $25+
If one or few large hedge funds or biotech/pharma focused small cap mutual fund(s) discovers this one and purchases 1 mln or few million shares, imagine what could happen !! I have seen many similar pharma stocks rise from single digit to triple digits. Hopefully this one will be another one someday imo !
#SupDup

https://t.co/NcACpzkVU7


Summary: Accumulating MBIO despite reverse-split risk; bullish on blood cancer science as M&A/licensing target for larger pharma.

$MBIO $0.28 - Under slow & steady accumulation. Why I am buying building a position? Click the link below from few months ago, read it fully.  I know there is chance of RS but despite I am accumulating given their science in treating #blood #cancer is so effective making it an attractive target for a strategic partnership/licensing or takeout by a larger pharma co imo
#SupDup

https://t.co/0HxY1ya5ps


Summary: Bullish LUNR; expects price to break above $6.

$LUNR - Lets it go above $6, it wants to imo
#SupDup


Summary: Holds SMCI long-term; expects value much higher in 2 years.

$SMCI ~$398 - Halted again quickly as soon as stock started rising after dipping to $373.
I think I need to just forget about this holding and stop looking at this stock for 2 yrs when its value may be much higher imo  😂
#SupDup


Summary: Accumulating CING with expectation of much higher prices near-term; bullish on ADHD/anxiety pipeline TAM.

$CING ~$5.15 Adding more and more slowly & steadily to sell someday at much higher prices in NT. Per mgmt:
Cingulate currently has 2 product candidates. CTX-01 and CTX-02 that are being developed to serve the approximately $22.1 billion annual US ADHD maket.  A 3rd product candidate CTX-2103 is being developed to serve roughly $5 billion US Anxiety market.
#SupDup


Summary: Bullish US renewables; Trump policy won't hurt sector given data center/crypto-driven power demand.

US renewable energy sector proxied by ICLN ETF

@DanielM_W It will all be time being. I don't think Trump admin will make any policy changes that will hurt renewable energy sector due to boom in hyperscale data centers, crypto miners and overall need for increased electric power imo

@SuperDuperInvst I am going to keep a core long term holding and have a smaller st holding to trade but I admit the election has hurt my confidence in renewables. Especially as the house has gone Republican too?


Summary: Barclays maintains SMCI price target at $693/share; author shares the bullish target.

$SMCI - Super Micro Price Target Maintained With a $693.00/Share by Barclays


Summary: Long VCIG; expects 100%+ upside within 1 year on SE Asian growth, Malaysia base, China stimulus, fast profitable growth, buyback, low market cap.

$VCIG $0.14 = Great Buy for ST, NT & LT given SE Asian economies are doing better especially #Malaysia where this company is based. #China should do well too now with the latest economic stimulus package.
Company is growing fast, profitable and have stock buy back that will initiate in NT. Diversified business lines with great growth potential. Current market cap is low making it an attractive buy. Stock with many ups and downs should be UP 100+% within 1 year imo
Check it out.
#SupDup #Pennystock #Pennypick


Summary: Conditional long SMCI to $465–$475 if Nasdaq turns green.

$SMCI - IF Nasdaq turns green it will spike to $465 - $475 range imo
#SupDup


Summary: SMCI is a screaming buy under $580 for both near-term and long-term; adding orders at $577–$571.

$SMCI $580 - Placed few more buy orders at $577 - $571 just in case it dips further. Stock will swing wildly in both directions but it is a SCREAMING BUY <$580 for both NT & LT investment imo
#SupDup


Going to start short selling again at $6.25+ ... more leaning towards again short selling on spikes imo

Summary: Plans to short LUNR again at $6.25+; heavy insider selling provides comfort for the bearish thesis.

$LUNR - Round 2, Going to start short selling again at $6.25+ after seeing dip to ~$5.50 earlier.
Someone knows something seems like it from the buying so far but lets see. Heavy insider selling gives me comfort but I am on wait and watch mode more leaning towards again short selling on spikes imo
#SupDup


Current co value $2 mln whereas cash on hand itself is $20 mln. Cancer drug pipeline that looks very promising for Ovarian Cancer. A larger pharma can take them out offering $100 mln which would be still dirt cheap value acquisition imo

Summary: Long ALLR under $1.50: trading below cash, promising oncology pipeline, thin float squeeze potential, and M&A takeout target at ~$100M.

$ALLR <$1.50 - Short covering someday could look like  Mother of all Squeezes due to thin float of 1.4 mln shares.
Current co value $2 mln whereas cash on hand itself is $20 mln.  Cancer drug pipeline that looks very promising for Ovarian Cancer. Look at the highly experienced management team and powerful recent hires.
A larger pharma can take them out offering $100 mln which would be still dirt cheap value acquisition imo
#SupDup


Summary: Bullish SMCI, AVGO, AMD, DELL, HPQ on sustained hyperscaler AI capex confirmed by Nvidia results and big-tech management commentary.

$NVDA down today but $SMCI up which makes think heavy short covering happening, existing investors buying more to cost average at lower prices and/or new big whales starting a long position. Irrespective one thing is sure that large companies are spending heavily on  #AI infrastructure which has been confirmed by yesterday's #Nvidia results & outlook. Also managements of $AMZN, $MSFT, $AAPL, $META, $GOOG etc. all have confirmed of their continued billions of dollars worth of spendings in AI Chips, Servers, Hyperscale Data Centers, and related technology which bodes very well for SMCI and other key players in the industry such as $AVGO $AMD $DELL $HPQ imo
#SupDup


bodes very well for SMCI and other key players in the industry such as $AVGO $AMD $DELL $HPQ imo


Summary: Holding and adding to KPRX on dips for short-, near-, and long-term; did not sell into spike.

$KPRX ~$3 .70 - I didn't sell any this morning on spike to $7.25+ but I am slowly adding & will be buying more on dips for ST, NT but mostly LT.
#SupDup


Adding more on dips for ST, NT & LT ... Current market cap of ~$25 mln makes this very attractive buy for NT & LT investors imo

Summary: Long CING at $5.70; adding on dips across all timeframes; $25M mkt cap seen as undervalued ahead of FDA approval and potential licensing deals.

$CING $5.70 - Adding more on dips for ST, NT & LT
Remember now they have added $10+ mln cash on hand which should get them through FDA approval of their lead phase 3 clinical trials stage #ADHD drug and any licensing deal(s) for their pipeline drug(s) and/or their unique PTR drug delivery mechanism would trigger massive rally down the road. Current market cap of ~$25 mln makes this very attractive buy for NT & LT investors imo
#SupDup


Summary: Adding to CING position to average down cost for near-term and long-term hold.

$CING $4.20 - Adding some more to cost avg for NT & LT
#SupDup


Summary: Adding to ALLR long at ~$1.50; undervalued vs book/cash, high short % sets up a spike on any catalyst.

$ALLR ~$1.50 - Adding some more for ST, NT & LT.
Just check the book value / cash position, and compare it with the current low market cap, float and short %.
This will one day suddenly spike like  🚀  once short covering starts on any good news imo.
#SupDup


$HUMA <$5.40 = SCREAMING BUY for ST, NT & LT. FDA approval chances for their Acellular tissue engineered vessel (ATEV™) BLA...are 90% to 95% based on my analysis

Summary: Strong buy on HUMA below $5.40 across all timeframes; 90–95% FDA approval probability for ATEV BLA expected within 45 days.

$HUMA <$5.40 = SCREAMING BUY for ST, NT & LT.
FDA approval chances for their Acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma are 90% to 95% based on my analysis of their data which should be announced any day within next 45 days imo
#SupDup


Summary: Long KPRX with LT PT $25+, currently ~$4; backed by $30M net cash, $300M+ licensing deal, and retained Asia rights plus pipeline optionality.

$KPRX ~$4 - 👀 👁 👁🗨  👀
Should be $10+ right now based on just its cash on hand of $30 mln with practically no debt. One of the pipeline drug has joint development & licensing deal for $300+ mln. Co still retains Asia rights. Other drug in development could fetch even a larger deal down the road for Global rights. Considering everything they have on their plate right now, this stock should be trading today near $18 if not higher which is why my LT PT is $25+ imo
#SupDup


Summary: Covered short at ~$5 and going long LUNR for day/short/near-term trade.

$LUNR ~$5 covered short, going long for DT/ST/NT
#SupDup


Summary: JP Morgan reiterates Overweight on NVDA, raises PT to $155 from $115.

$NVDA $123 - Nvidia maintained at Overweight, Price Target Raised to $155.00/Share From $115.00 by JP Morgan
#SupDup


Summary: Anticipates positive catalyst for CING; bullish on upcoming news.

@VVaannccEE Yes. Good news coming, I smell something good cooking imo

@SuperDuperInvst $CING
We know how easily it moves, I figure there's anticipation of news soon on the last test results or one of the upcoming patents!


Summary: Actively adding to VCIG position on dips for short-to-near-term trade at ~$0.15.

$VCIG ~$0.15 - Adding heavily on dips for ST/NT
#SupDup


Summary: Bullish on VCIG; Malaysia-based penny stock expected to do well going forward.

$VCIG $0.135 - Read this entire article and see why this Malaysia based company is and will be doing great in future imo
#SupDup #Pennystock

https://t.co/GJjoTIZoDl


Summary: Shorting ASTS at $30+ after yesterday's $22.50 print, trading the daily $2–$4 swings.

$ASTS $30+ time to Short for me now after seeing it at $22.50 yesterday.
Love the almost daily $2 to $4 rise and fall providing great opportunity to make $ trading in both directions imo
#SupDup


Summary: Long FSLR with $240+ target; called the dip to $195 a great add opportunity.

$FSLR $240+ rn
It was great opportunity to add on recent dip to $195 imo
#SupDup

https://t.co/ChLtNjfR80

Gimme Gimme Gimme more $FSLR <$215
#SupDup


Summary: Holding ALLR and plans to add on further dips.

@engmohammadM I am holding $ALLR and plan to double if I see further dips


Summary: Active open buy order for 2,000 shares of ALLR; position still live.

$ALLR - Still open   🤔
Order Placed Buy 2,000 ALLR Limit Day 10/29/24 11:14:02 AM EDT
#SupDup


Summary: Bullish CING on licensing deal for ADHD drug CTx-1301 heading toward NDA filing; sees 100–1000% upside.

$CING <$3.40 - US & Global rights licensing deal for its very effective lead #ADHD drug asset CTx-1301  in phase 3rd ready to file NDA with FDA could make this stock rise 100% to 1000% someday imo
#SupDup


Summary: Avoid NKGN; decisive bearish stance with multiple unstated reasons.

@barottrushar2 I would avoid it for several reasons.

@SuperDuperInvst Any suggestions on $NKGN ?


Summary: Bullish CETX on thin float, cheap valuation, and recent multi-million dollar contract wins; expects 2-3x near-term.

$CETX $0.29 - Thin equity float and dirt cheap current valuation. Co has been winning multi million $ contracts lately.  Easy double or triple in NT imo
#SupDup


Summary: Relays Mizuho Underperform on PLTR with PT $37 (vs ~$51.50 current); adopts bearish stance by sharing it.

$PLTR $51.50
Palantir Technologies maintained at Underperform, Price Target Raised to $37.00/Share From $30.00 by Mizuho
Palantir Technologies maintained at Market Perform Price Target Raised to $38.00/Share From $35.00 by  Northland Capital Market
#SupDup


Summary: Considering short selling LUNR after locking gains; bearish near-term (day/swing trade).

$LUNR $5.80+  Selling from last week purchases at ~$4.75 to lock 25% quick gain and may even start Short Selling for DT/ST imo
#SupDup


Summary: Buy LUMN after Kerrisdale short-seller attack; historical pattern shows quick recovery and gains post-tumble.

$LUMN - Short seller Sahm Adrangi's firm Kerrisdale Capital attacked it today. I remember him doing the same last year with $AI that tanked initially on accounting fraud and other bs allegations by them but recovered fully and went up even higher than where it was very quickly.  I feel he does insider info based illegal trading too imo.
If you do data analysis, there is a very predictable pattern in most cases. Stock tumbles intially which is when you start buying and recovers eventually which is when you sell and lock your gains. The whole cycle doesn't take too long from my past observations imo
#SupDup


Summary: Buying LUNR on dips for short-to-near-term.

$LUNR ~$4.55- Buying on dips for ST/NT
#SupDup


Summary: Still short ASTS; shorted at $36–$39 on fundamental overvaluation, down 25%+ already with continued bearish view.

$ASTS <$28 now, last week when I said it was time to short sell and was shorting at $36 - $39 given its overvaluation based on fundamentals, I got bombarded with messages saying I had no clue and was making a mistake. Its down now 25+% already. But lately all those bulls are quiet imo
#SupDup


Summary: Bullish on three small-cap biotechs trading below cash with phase 2/3 pipeline catalysts: ALLR (ovarian cancer), KPRX (vision loss + strategic deal), CING (ADHD/anxiety).

$ALLR <$1.40 (<$2 mln value, ~$20 mln cash), Powerful Anti Ovarian #Cancer drug in phase 2
$KPRX $3.60 (~$10 mln value, ~$30 mln cash), Vision loss related effective 2 drugs in phase 2 with $370+ mln strategic deal in place for 1 of its drug.
$CING <$3.50 (<$20 mln value, ~$20 mln cash), Very promising #ADHD & Anxiety drugs in phase 3).
#SupDup


$KPRX $3.60 (~$10 mln value, ~$30 mln cash), Vision loss related effective 2 drugs in phase 2 with $370+ mln strategic deal in place for 1 of its drug


$CING <$3.50 (<$20 mln value, ~$20 mln cash), Very promising #ADHD & Anxiety drugs in phase 3


Summary: Bought LUNR on dips at $6.85 for short-term trade.

$LUNR ~$7.50  🤑
#SupDup

https://t.co/JB7xgdAYs8

$LUNR - Bought some on dips at $6.85 for ST
#SupDup


Summary: Bullish VVOS; author characterizes it as under slow and steady accumulation.

$VVOS - Under slow & steady accumulation
#SupDup


Summary: Considering adding to existing long position in VCIG at $0.13.

$VCIG $0.13 - Inching up slowly, I am thinking of adding some more.
#SupDup


Summary: Bullish SMCI; dismisses bearish analysts and short sellers, citing strong and growing demand.

$SMCI - Business is growing with strong demand so don't believe the BS analysts or short seller spewed imo
#SupDup

🌎We are excited to share that a number of our Supermicro servers have been registered in EPEAT, the world's premier ecolabel for electronics and technology products. Learn more: https://t.co/6xWkXWo5tt

#Sustainability #GreenIT #EPEAT #Supermicro  #DataCenters #greencomputing https://t.co/UJFSOueKXP


Summary: Bullish ALLR; excited by Phase 2 early conclusion on clinical benefit and potential FDA accelerated approval pathway for stenoparib.

$ALLR - I am excited due to the below that management had said. May be they can use FDA's accelerated approval program? (Details below)
The Company has concluded its Phase 2 clinical trial of stenoparib early due to clear clinical benefits observed, including tumor shrinkage and long-term disease stability, in heavily pre-treated ovarian cancer patients. Using Allarity’s DRP® companion diagnostic to pre-screen patients, the trial targeted those most likely to benefit.

FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint.  A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.

Drug companies are still required to conduct studies to confirm the anticipated clinical benefit. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug.  If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.

Any expert on this please share your views on above.
#SupDup


Summary: Initiating short on AMD after ~$20 run-up from $132 to $151.50.

$AMD ~$151.50 rn, 5 days ago it was at ~$132  😍
Getting ready to start a short position.
#SupDup


Summary: Shares multiple analyst Buy/Outperform/Strong Buy reiterations with raised PTs ($140–$145) on NVDA post-ER; endorses bullish consensus.

$NVDA $120 - Analyst ratings this morning after ER.

Maintained at Buy, Price Target Raised to $145.00/Share From $120.00 by Needham

Maintained at Outperform, Price Target Raised to $140.00/Share From $132.00 by Mizuho

Maintained at Strong Buy, Price Target Raised to $140.00/Share From $120.00 by Raymond James
#SupDup #Nvidia


Summary: Buy and hold GNLX for 3 years; one catalyst could spike it 100%+.

$GNLX $2.15 - Buy and forget for 3 yrs as if you put money in CD. Will be amazed to see the returns upon maturity or before end of term. One big news and stock can spike 100% easily imo
#SupDup


Summary: Actively accumulating VCIG at ~$0.20, expecting big news within 2 weeks; bullish short-, near-, and long-term.

$VCIG ~$0.20 rn - Expecting big news one day within next 2 weeks imo
I am slowly & steadily adding more & more for ST, NT & LT.
#SupDup


Summary: Buy VCIG for further gains after taking profits from QH.

Bring your $QH profits to $VCIG and make more $ imo
#SupDup #PennyStock


Summary: Building a large long position in HOUR across short, near, and long term; thin float with 95% mgmt ownership cited as catalyst.

$HOUR $1.40 - Thin equity float of just 1.6 mln shares with 95% holding of mgmt  =   🔥 🚀  imo
I am building a large long position for ST, NT & LT. Join me if you like what you see.
#SupDup


Summary: Bullish HOUR on accelerating revenue growth from $132M to $165-250M in 2024 and continued strengthening beyond.

$HOUR - From 2013 to 2023 company grew its sales from 0 to $132.1 mln
In 2024 mgmt is projecting sales of $165 mln to $250 mln which will be huge spike and going forward I believe it will only get stronger & stronger with higher profits imo
#SupDup


Summary: Watch GNLX for multiple near-term data readouts; implied bullish catalyst ahead.

$PCVX - UP 43% this morning on news that Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial.
Multiple data read outs are expected from $GNLX in NT so keep your eyes on it imo
#SupDup


Summary: Sees $0.77 as a good reentry point for GRI for another run higher.

$GRI $0.77 - Looking good reentry point for round 2 after its recent spike to $2+ imo
#SupDup


Summary: Author endorses Ellison's view that AI infra boom lasts years; tags SMCI, NVDA, AMD as beneficiaries.

Few weeks ago I said #AI is here to stay for a very long time. Below is what $ORCL CEO Larry Ellison said after its ER:
#SupDup $SMCI $NVDA $AMD

Larry Ellison has a message for the artificial-intelligence infrastructure  skeptics: The current boom will last for years, and not end soon.

When asked on Oracle's Monday earnings conference call about the sustainability the latest wave of AI model training infrastructure spend, the executive was optimistic.

"If your horizon is over next five years, maybe  even the next ten years I wouldn't worry about it," Oracle's founder,  chairman, and chief technology officer said. "This business is just growing larger and larger and larger. There is no slowdown or shift coming."


Summary: Bullish GRI both near- and long-term; price inching up from dip, sees it much higher.

$GRI $0.82 rn, slowly inching up again after the dip from recent spike to $2.25
I see this much higher both in NT & LT with many ups & downs imo
#SupDup

https://t.co/s6gGID1vdW

$GRI $0.72 - Doubling my long position on dip from $2+
#SupDup


Summary: Buying ATLX dips; expects price to rise into teens within 6 months.

$ATLX <$7.40 - Loading up on dips for ST & NT
Investors with patience should see this one rise into teens within next 6 months imo
#SupDup #Lithium


Summary: Short GNLN; author reaffirms $5 downside target from current ~$6 level.

$GNLN $6 rn, Almost there to $5 as I had predicted couple of weeks ago on spike to $17.75 imo
#SupDup

https://t.co/x9iWJ18rdA

$GNLN $17.25+ = Great Short Sell imo
#SupDup


Summary: Speculative long GRI targeting $1+ by Monday on potential positive news catalyst.

$GRI $0.65 - 50% chance we will see it at $1+ on Monday morning. If we hear any good news from the company this will really liftoff strongly  🔥 🚀  imo
#SupDup


Summary: Bullish ALLR: believes market maker manipulation will end and MMs will have to cover/square their short positions.

$ALLR - Total MM manipulation going on. You will notice there will be buy orders for 1000, 2000, 5000, 10000 shares that will immediately drop the price by a few cents with a 100, 200 shares sell.
Lets see how long can MM keep playing the game and can keep the lid tightly under their control.
Eventually they will have to give up and start squaring up their position imo
#SupDup


Summary: Sarcastic bear-baiting on ALLR; real stance is bullish — thin float, 10x cash, strong pipeline, heavy mgmt holding make it a short-squeeze candidate.

$ALLR $1.60 - More they short, better it will be. So please keep short selling, this is POS co lol.
Check out $DRUG price moves at the link below to see how that stock went from $1 to ~$80 within days. Look at the current market cap and the rise just within last 7 days.
Not saying this one will do the same but shorts should learn to never short a very thin float stock with 10x cash on hand, promising business pipeline and heavy management holding imo.
#SupDup

https://t.co/VDvSuRO1sm


Summary: Initiating short on UPST at $85.50+; fair value $65, stop loss $88.50 — views current price as dangerously overvalued.

$UPST $85.50+ = DANGEROUSLY OVERVALUED currently based on ALL THINGS CONSIDERED.
Fair price should be no more than $65 currently imo.
I am going to start short position with a stop loss at $88.50
#SupDup


Summary: Bearish UPXI: weak fundamentals, huge debt, imminent dilutive capital raise expected given cash-strapped balance sheet.

$UPXI $8 - Jumped today to ~$16 at one point rising 300% due to recent reverse split and thin float. But be careful guys chasing it. Its fundamentals are very weak. Just see the last Q ER. Debt is huge. They will do a capital raise for sure given they are cash strapped imo
#SupDup


Summary: ASTS can spike on any positive catalyst; soft bullish stance on the speculative name.

@JasonCh93093500 $ASTS - It is a speculative stock so upon any good news or positive development stock can spike imo.

@SuperDuperInvst Thanks for the reply. Any opinion on the end of the year rally or have all the energy been spent?


Summary: Adding to long ALLR at $1.50; warns shorts referencing thin-float squeeze history.

$ALLR $1.50 - Adding even some more bringing my profits from other recent high fliers.
Shorts beware, Don't forget what happened with other thin floaters $GNPX & $DRUG
#SupDup


Summary: Long FSLR below $195; author sees current dip as a buying opportunity for near- and long-term investors.

$FSLR < $195 - Great buying opportunity on dips for both NT & LT investors imo
#SupDup


Summary: Bullish CING at ~$25M valuation; sees it rising sharply once institutional investors discover it, analogous to SMMT's run.

$SMMT $32.50 rn - Summit Therapeutics stock went up from <$2 to new 52 week high today despite their capital raise of $235 Million yesterday at $22.70/share.
It is worth now ~$24 bln  😍
Compare its fundamentals, pipeline and valuation with $CING $5.40 low valuation of ~$25 mln. I don't see why Cingulate can't rise much higher similarly once big players discover and start investing imo
#SupDup
https://t.co/8vVzoy51JJ


Summary: Shares Morgan Stanley Underweight on PLTR with $20 PT, implying ~53% downside from $43.

$PLTR $43 - Morgan Stanley has $20 PT with Underweight rating  😍
#SupDup


Summary: Long CING; up 10% in a day but expects significantly higher prices long-term.

$CING ~$6.50 - UP 10% within 1 day but in LT it will be way higher imo
#SupDup #Money #FastMoney

https://t.co/mXSW0CDnjH

$CING $5.85 - VERY ATTRACTIVE takeover candidate at dirt cheap valuation for a large multinational Pharma giant like Pfizer, Merck, Johnson & Johnson, Novartis, Roche, Sanofi, Astra Zeneca, Bristol Myers Squibb, Amgen, Eli Lilly, Ranbaxy Labs, Abbott, Sun Pharma, Boeringer


Summary: SMCI heading to $50–$60 within 2 weeks, implying a significant decline from current levels.

$SMCI - Marching towards $50 - $60 range within next 2 weeks imo
#SupDup


Summary: Bullish on KPRX ahead of upcoming KIO-301 trial results; expects positive outcome.

$KPRX - Kiora's investigational treatment for retinitis pigmentosa, KIO-301, demonstrates visual function restoration in patients who are blind, listen to this patient testimony.  This was last year, can't wait to see the soon to be announced trial results imo.
#SupDup
https://t.co/kaBtKsHQS4


Summary: Adding ALLR at $1.75; razor-thin 1.5M float + trades <12x cash = stock should be $10+; expects short-squeeze style surge similar to GNPX.

$GNPX - It took an hr after I shared that long trade idea yesterday at $0.47 before it really started taking off and rest as we know surge of 700+%. Shorts kept shorting but had to give up and made it spike like crazy due to mother of all short squeezes happened.
$ALLR $1.75 - I see a lot of similarities. I will be adding more and hold tight given float is razor thin at just 1.5 mln shares. Trades under ~12x cash on hand so even based on just cash on hand stock should be at $10+ rn imo
#SupDup


Summary: Long gold as a long-term safe bet.

@wallstreetbets Gold is always a safe LT bet imo

JUST IN: Gold hits a new all time high 📈 https://t.co/wM9TK8k0fH


Summary: Bullish GNLX: sufficient cash runway into Q1 2026, late-stage oncology pipeline, potential licensing upside without dilution risk.

$GNLX - I don't like biotechs that are cash strapped and keep raising money diluting existing stock holders.
With Genelux they have late stage product for hard to treat Ovarian Cancer along with others and have sufficient cash on hand to last long as per mgmt.  Any licensing deal for pipeline drug(s) could bring more $ imo.
Cash, cash equivalents, short and long-term investments were $40.4 million as of June 30, 2024. The Company expects its existing cash, cash equivalents, short and long-term investments will provide runway into the first quarter of 2026.


Summary: Adding to long position in GNLX at $2.15.


Summary: FSLR at ~$213 seen as attractive buy for day/short/near-term after pullback from $260.

$FSLR ~$213 seems very attractive buy for DT/ST/NT given stock has dropped from recent spike to $260 imo
#SupDup


Summary: Strong buy on GNLX under $2; expects 100–500% gain within 3 years on cancer drug pipeline licensing and China deal potential.

$GNLX <$2 - Time to LOAD UP if you have patience, within 3 yrs this will be UP 100% to 500% for sure given their late stage promising hard to treat cancer drugs pipeline licensing & sales potential in the future.
For just China rights they got $171 mln in LT deal imo. Read PR at below link.
#SupDup

https://t.co/IuAgINyzFv


Summary: Long KPRX at $3.60 on retinal drug pipeline, $300M+ deal with Thea TOI, cash runway into 2027, and multi-billion dollar sales potential.

New Stock Pick:
$KPRX $3.60 - Kiora Pharmaceuticals, Inc. progressing drug developments for Retinal Diseases to Slow, Stop or Restore lost Eye Vision  👀
Current Value: ~$10 mln, 3x Cash on hand of ~$30 mln (Expected runway into 2027)
Equity float: 1.36 mln shares
$300+ mln potential deal in place with upto 20% royalties on sales for one of its development drug KIO-301 with European Ophthalmic giant Thea TOI (Excluding Asia rights). Thea TOI paying quarterly for drug development/other milestone payments.
KI0-104 Worldwide rights still owned by Kiora. Company is exploring licensing/strategic  partnerships)
Huge multi billion dollars USA & Global sales opportunities upon approval of drugs.  Great NT & LT buy imo.
#SupDup


Summary: Bullish ALLR on cancer tumor shrinkage data and billions in global sales potential via FDA approval and licensing deals.

$ALLR - CANCER TUMOR SHRINKAGE & Help with #CANCER means BILLIONS of $$$$$$$$ global sales potential down the road with FDA approval. Can't wait to see mgmt line up licensing deals for USA and rest of the world with a big phama multinational imo
#SupDup


Summary: Holding GRI long-term, comparing potential to WGS/DRUG multi-bagger runs.

$GRI $1.10 rn - Can it do what $WGS (<$1.20 to $62 in last 1 yr) or $DRUG (<$1 to $79 in last 1 yr) stocks did? Lots of similarities between the companies.
Will see what happens in LT but I am going to keep some for long unlike having quickly sold the other one and missed out on the jackpot imo
#SupDup


Summary: Expects GNPX management to do a dilutive capital raise following the 500%+ spike, implying downward pressure.

$GNPX - I feel mgmt should do/Will do a capital raise taking advantage of the 500+% spike within 2 days imo
#SupDup


Summary: Bullish on HOUR; expects strong holiday sales/profits with fair value at $5+.

$HOUR - Holiday shopping gonna be SOLID this year. Even though the mgmt seems very conservative,  company will be huge beneficiary as they are anticipating strong sales and profits. Fair stock price even today considering everything should be $5 or higher imo.
#SupDup


Summary: Short UPST from $81+; expects drop to $68–$75 or lower near-term.

$UPST $81+ = Time to lock gains. Sell/Short Sell it will drop to $68 - $75 range or even lower in NT imo
#SupDup


Summary: Accumulating GRI at $0.53 for short, near, and long term; expects double/triple or more on thin float biotech.

$GRI $0.53 - Bring some of your $DRUG,  $ATNF & $WGS profits to possibly double, triple or even make more money down the road with this emerging biotech stock with thin float and huge potential. I am accumulating for ST, NT & LT.
Learn about the company & its pipeline at: https://t.co/7M4Uq8Mk9K
#SupDup


Summary: Long KPRX at $3.50, expecting a similar ~350% rise to AAOI in the future.

@wallstreetbets Check $AAOI its at $27 - UP 350%   🤑, Load up $KPRX $3.50 for similar rise in future imo.
#SupDup

https://t.co/bzeQgBGElM

what stocks or crypto are we buying today!? 👇


Summary: Buying SMCI on dips at ~$419 across all timeframes (day, short, near, long term).

$SMCI - Buying on dips at ~$419 for DT, ST, NT & LT
#SupDup


Summary: Bullish AAPL: new AI-chip iPhone design expected to trigger a buying frenzy.

$AAPL - Reached market cap of $3.4 Trillion. Expecting its new iPhone design should trigger a buying frenzy due to #AI chip imo
Apple's M4 chip includes a Neural Engine that's designed to speed up AI workloads. The Neural Engine can perform 38 trillion operations per second, which is 60 times faster than the first Neural Engine in the A11 Bionic chip. The M4 also includes next-generation ML accelerators, a high-performance GPU, and unified memory with higher bandwidth.
#SupDup


Summary: Adding to SMCI position below $590 for short-term and near-term.

$SMCI - Adding <$590 for ST & NT
#SupDup


Summary: Bullish TRUG; author pitches it as the next multi-bagger after LAES ran 2000%.

$LAES $7.40 rn - UP 2000%   🤑   💰  since  👇
Don't missout on $TRUG if you did with my other multi bangers imo
#SupDup

https://t.co/7U3DpVPlfO

$LAES $0.37 - I am loading up. Do your indepth DD and if you like it, Start LOADING UP all you penny stock lovers. It can quickly rise to $1 - $3 in 2025 or sooner given currently the company is undervalued and that they plan to launch 2 new very exciting Quantum Resistant Chips


Summary: All four small biotech stocks forecast to 100%+ gains in 2025; advises loading up.

$KPRX $3.30
$ANVS $5.15
$CING $4.85
$ALLR $1.15

Above 4 biotech stocks will see 100+% rises in 2025.
Do your DD and if you like 1 or all of them, start loading up but only if you have patience, vision and risk tolerance imo
#SupDup


Summary: Shares BofA Buy reiteration on TSLA with PT raised to $400.

$TSLA $373 - Bank of America has increased its price target for Tesla Inc. from $350 to $400, maintaining a Buy rating.
#SupDup


I am loading up non stop because I see that their Anti #Ovarian #CANCER drug is Super Duper and down the road could be MULTI BILLION $ sales potential if & when its gets FDA approval. With $18 mln cash on hand how the F is this stock trading at <$1.20 valuing the co at joke < $2 mln only.

Summary: Loading up on ALLR; anti-ovarian-cancer drug has multi-billion potential, genomic lab generating revenue, clean balance sheet, stock massively undervalued vs $18M cash, expects short squeeze + 300% surge.

$ALLR - Sorry mind my language but who the F is this seller that keeps selling or shorting non stop?  I am loading up non stop because I see that their Anti #Ovarian #CANCER drug is Super Duper and down the road could be MULTI BILLION $ sales potential if & when its gets FDA approval. Their Genomic testing lab is now generating revenues from other biotechs. With $18 mln cash on hand how the F is this stock trading at <$1.20 valuing the co at joke < $2 mln only.
Clean balance sheet with no debt, no warrants lingering or any dilutive instruments. Once their past issue with SEC gets cleared up (which should with some disciplinary action/fine) this will be  🚀 🚀 🚀
One day there will be MOTHER OF ALL SHORT SQUEEZES like $DRUG $ATNF spikes few weeks ago I hope and at that time the thin float comes into play. Can't wait the day when we see 5 mln shares volume and price surging 300% imo
#SupDup


Summary: Still holding CING; expects it to eventually break out of the current range.

@DanjeTG Yes I am, it will have its day imo

@SuperDuperInvst Are you still holding out on $CING? Seems like it’s hard stuck in the 4-4.45 range


Summary: Bullish TRUG under accumulation, expects price to rise out of penny stock territory.

$TRUG - Under slow and steady accumulation.
Keep your  👀 on it. Its gonna march towards getting out of penny land imo
#SupDup


Summary: Plans to add more KSCP across short, near, and long term after seeing the AI security robot footage.

industry='Security & Protection Services'

$KSCP  $11.25 -  😍  Wow !   🤑
I plan to add lot more for ST, NT & LT after seeing this AI powered security robot imo
#SupDup

In case you are wondering if #SecurityRobots are visible at night and an effective #deterrent, check out this footage from one of our client locations.  And with 360-degree cameras, it's head is always on a swivel!

Learn more: https://t.co/FEPPdFa5zN https://t.co/rPHEMPJVcE


Summary: Hold INTC; expects massive turnaround starting 2025.

@ChrisBigMonies I would hold, $INTC $20.30 will have a massive turnaround starting 2025 imo

@SuperDuperInvst I have 10 long term (1 year) calls on INTC…wondering if I should sell them for a 5% loss or hold and hope for the duration of 2025


Summary: Bullish KPRX: thin float, Goldman accumulating, cash ~3x market cap; author sees fair value at $10+.

$KPRX $3.55 - Equity float is Super thin with just 1.36 mln shares. Now that Goldman Sachs have started buying and loaded ~181,000 shares imagine IF they or another other institutional investor loads up like a 1 mln shares.
what can happen ???   😍
Cash on hand is about 3 times the current market value of this company. This should be a 10+ stock even today imo
#SupDup


Summary: Bullish KSCP on Verizon partnership for K5 security robot connectivity deployment.

$KSCP - Don't forget their recent deal with #Verizon $VZ a $160 bln telco giant imo. Click url below.
#SupDup

Verizon Partners with Knightscope to Power Connectivity for Advanced Public Safety Technologies
Thu, 14 Nov 2024 10:35:00 -0400 | Business Wire
Knightscope's K5 GOV Autonomous Security Robot has Received FedRAMP Approval to Serve the U.S. Department of Veterans Affairs

Knightscope, Inc. (NASDAQ:KSCP) ("Knightscope" or the "Company"), an innovator in robotics and artificial intelligence ("AI") technologies focused on public safety, today announces a partnership with Verizon Business to provide secure, reliable connectivity for the deployment of Knightscope's K5 security robots and K1 emergency communication devices to help elevate safety at commercial and government facilities.

https://t.co/nMF5R6TaKv


Summary: Buying into KSCP and MOB; inviting others to join.

Loading up $KSCP & $MOB - Feel free to join me if you like.
#SupDup


Summary: Long CING at $4.30; expects positive catalyst within 1 month, recommends buying every dip.

$CING $4.30 - I am expecting some good news within 1 month so investors with patience every dip would be great buying opportunity.
One day in future this stock will 🔥  🚀 like $LUNR & $RKLB  imo
#SupDup


Summary: Author shares/endorses two Buy reiterations with raised PTs ($230 Truist, $226 Needham) on DECK, implying continued upside from $203+.

$DECK $203+  🤑
Maintained at Buy, Price target raised to $230.00/share from $205.00 by Truist Securities
Maintained at Buy, Price target raised to $226.00/share from $218.00 by Needham
#SupDup

https://t.co/6gaVJ6UTLl

$DECK < $155 - Good opportunity to buy for ST & NT imo
#SupDup #Hoka #Deckers


Summary: Adding to long position in RR on dips at $3.15–$3.20 across short, near, and long-term horizons.

$RR - Adding more on dips at $3.15 - $3.20 range for ST, NT & LT
SupDup


Summary: Bullish RR on rising service robot sales; potential SOUN tie-up would benefit both companies.

$RR - Their service robots sales are rising, here's a robot seen at a restaurant in NJ, USA bringing food to the table of customers. Notice the name on the robot  😍
This company is going to be MONSTER in the future, if they and $SOUN tie up it will be great for both companies imo.
#SupDup


if they and $SOUN tie up it will be great for both companies imo


Summary: Adding RR at ~$1.30 for short, near, and long-term holding.

I am adding $RR ~$1.30 for ST, NT & LT
#SupDup


Summary: Bullish KSCP; expects price to reach teens.

$KSCP - Gonna be teens so get ready to celebrate imo  🥳  🎉
#SupDup #AI #Security #Safety #Robot


Summary: RR undervalued at $3 vs SERV at $19.70; should be $10+ given broader multi-industry robot portfolio.

$SERV $19.70+ with just 1 last mile food delivery robot product comparatively $RR $3 with multiple robots catering to wide variety of service industries should be $10+ rn all things considered imo
#SupDup


Summary: Loading TSSI under $12.40 for short/near/long-term; 2025 price target $25+.

$TSSI <$12.40 - I am loading up for ST, NT & LT
My PT for 2025 is $25+ imo
#SupDup


Summary: Bought MSTR on dips as a Bitcoin proxy play.

@TiffanyFong_ Didn't buy any #Bitcoin but loaded $MSTR on dips that owns a boat load of them imo.
#SupDup

https://t.co/LjzGAvqsq7

BITCOIN JUST HIT $99K LET’S FUCKING GO!!!


Summary: Bought TSLA on dip below $430; live long position.

@GrindeOptions Bought small lot today on dips at <$430

If you’re a long term $TSLA bull, leave your mark on this post below.

We stand together united on days like today. 💪 https://t.co/SUQL97QQ0y


Summary: Offhand bullish mention of Richtech Robotics as a relevant play on service robotics.

@TiffanyFong_ lol 😂
Talk to $RR Richtech Robotics they can help you imo

can someone please invent a robot that just plays with my hair all day long ??? 🥺


Summary: RR is undervalued at $1.20 vs comparable SERV at $15+; author sees fair value at $4+.

$SERV $15+ ($675 mln value), comparatively $RR ~$1.20 ($115 mln value) should be at least $4 if not higher imo
#SupDup


Summary: Long XAIR: trades at cash value, no dilution risk until mid-2026, sales surge expected in 2025, FDA PMA supplement catalyst upcoming.

$XAIR - Trades at cash on hand value. Cash to last until mid 2026 so possibly no fear of dilution.
Sales will surge in 2025, this is the time to buy and hold.  NT Catalyst - Cardiac surgery PMA supplement review ongoing at FDA which will bring a lot of attention with that news down the road imo
#SupDup


Adding more for ST, NT & LT. I see the stock rising to $25+ in 2025

Summary: Adding TSSI at ~$12.50 with $25+ target in 2025 on hyperscale data center and AI tailwinds.

$TSSI ~$12.50 - Adding more for ST, NT & LT
I see the stock rising to $25+ in 2025
Great play to benefit from Hyper Scale Data Center & AI boom imo
#SupDup


Summary: Buying INTC below $21.20 across multiple timeframes from day-trade to long-term.

$INTC <$21.20 - Starting to buy in lots for DT/ST/NT & LT
#SupDup


$TPL $1700+ = SELL SELL SELL, Lock your profits on this massive spike. Be careful chasing it here imo

Summary: Sell TPL at $1700+; warns against chasing after a massive spike, urging profit-taking.

$TPL $1337 today, What did I say recently?   👇
#SupDup

https://t.co/gxs0s8kB0b

$TPL $1700+ = SELL SELL SELL, Lock your profits on this massive spike. I have been following this company for years since its stock was <$500.
Be careful chasing it here imo
#SupDup


Summary: Long RR with target $3–$5+ in 2025 from current ~$0.75–$0.80; recommends loading up.

$RR $0.75 - $0.80 - Will be $3 - $5++++ in 2025
Start loading up if you have vision and some patience imo.
#SupDup


Summary: Long INTC as a major beneficiary of the AI PC and tablet buildout trend.

$INTC - Will be huge beneficiary of  👇  imo.
IDC Says PC and Platform Makers are gearing up for AI PCs and Tablets to be the Next Big Thing.
#SupDup


Summary: Bullish XAIR; CE Mark in hand, PMA cardiac surgery approval is the next near-term catalyst.

$XAIR - Now they have CE Mark approval for Europe, PMA Approval for Cardiac surgery decision is next NT catalyst imo
#SupDup https://t.co/tFy1vYv0MZ


Summary: Long TRUG at current depressed price; NT PT $1–$3, LT PT $5+, citing mkt cap below sales, high insider ownership, and 82% YoY revenue growth.

$TRUG - Remember  👇
TruGolf Holdings, Inc. has current mkt cap of $9 mln, whereas 2023 sales were $19+ mln.
Small equity float of 3.4 mln shares. Insider holding is 66+%
Strongly rising 3rd Qtr'24 revenues were $6.25 mln, UP 82% YoY basis with rising Gross Margins at 69%.
This is a Golf/Gaming & Multimedia Technology company using now AI. Offers Hardware & Software products for all you #GOLF lovers worldwide.
52 week high is ~$12 so at current low price I see it as bargain buy for ST, NT & LT investors.
My NT PT is $1 - $3, LT PT is $5+  imo.
Do your DD & if you like it, feel free to join me on this investment.
#SupDup


Summary: Shares/endorses Guggenheim Sell on TSLA with PT $175, well below current ~$372.

$TSLA $372 rn  👇  🤔  Wonder what this analyst knows  😂
Tesla maintained at Sell, Price target raised to $175.00/share from $156.00 by Guggenheim
#SupDup


Summary: RR undervalued at $0.92 vs SERV; should be at least $3 given better products, Nvidia partnership, and McDonald's testing.

$SERV $14.50+ rn, $RR $0.92 should be at least $3 rn comparatively if not higher.
Richtech Robotics is way better products wise than Serve Robotics. Remember RR is working with Nvidia and testing their service robots at McDonald's imo
#SupDup


Summary: Still holding all named biotech picks; expects most to be at much higher prices by 2025 on catalysts like trial results, licensing deals, or buyouts.

I know some of my biotech picks are down or dead for now but you all may know Pharma stocks take a while to rise but when they have great news about positive results from their clinical trials or they get licensing deal for their drug or buyout, they skyrocket suddenly and rise like a 🚀
In 2025 we should see most of them at much higher prices than they are today imo.
Patience folks I am still holding all of those stocks and not worried at all.
#SupDup $KPRX $ALLR $GNPX $CING $MBIO


Summary: Bullish KSCP; expects price to move from sub-$12 into teens in the short term.

$KSCP <$12 - Get ready to welcome it into teens in ST imo   🤑
#SupDup


Summary: Loading up on TRUG below $0.60; expects significant upside similar to past multi-bagger calls.

$TRUG <$0.60 - Investors with patience & vision should do their DD and if you like it, start LOADING UP like I have been. Now please don't me make sound like a paid pumper or screamer Booyah guy like I had to do with $LUNR $LAES $RKLB $LITM $WKEY $HOUR $LUNRW and several other multi bangers that went up 100+% to 2000% very quickly in past few months imo.
#SupDup


Summary: Author highlights ANVS hitting $8.25+ pre-market, referencing prior 100%+ rise prediction as validation; bullish on continued move.

$ANVS $8.25+ in pre mkt    🤑, Remember   👇
#SupDup

https://t.co/Orcyrx4vAt

$KPRX $3.30
$ANVS $5.15
$CING $4.85
$ALLR $1.15

Above 4 biotech stocks will see 100+% rises in 2025.
Do your DD and if you like 1 or all of them, start loading up but only if you have patience, vision and risk tolerance imo
#SupDup


Summary: TSSI should double or triple by year-end from current $11.50.

@ChrisBigMonies $TSSI $11.50 - Should double or may even triple this year with many ups & downs imo
#SupDup

@SuperDuperInvst Not bad at all…$TSSI recovering nicely as well


Summary: Bullish KSCP; urges holding with vision and patience or risk missing a future run like prior picks.

$KSCP - Don't be without it if you have vision & patience or else you gonna feel like not buying $LAES $WKEY $TSSI $LITM $RR $AAOI $LUNR $LUNRW $OPTT and few others when I first mentioned about them respectively imo    🤑   💰
#SupDup


Summary: Expects dilutive capital raises for both LAES and WKEY within 3 months; implied caution/bearish.

$LAES $3.45 - $WKEY $13
I expect decent size capital raises within next 3 months so keep that in mind imo
#SupDup


Summary: Buying INTC below $23 for day/swing/near-term trades and long-term; recommends adding on dips.

$INTC <$23 - Buying for DT/ST/NT. Great LT buy for investors with capacity to add more on any further dips and have patience imo.
#SupDup


Summary: Bullish TRUG on massive global potential for AI-powered indoor golf arenas, likened to Dave & Busters for golfers.

$TRUG - You see outdoor #golf practice ranges almost in every major towns & cities of #USA. Now add all foreign countries, the potential for this new concept of Golf learning, practicing & mastering is huge with this company's AI powered hardware & software based indoor arenas. A concept like Dave & Busters $PLAY for golfers would be huge success all over given golf is a sport that is growing fast imo.
Play, Eat & Drink = Complete entertainment    👋
#SupDup


Summary: MBIO slowly inching up from $0.26; bullish lean.

$MBIO $0.26 rn slowly inching up imo
#SupDup

https://t.co/D4fotEZO3v


Summary: Expects strong gap-up open tomorrow for crypto-linked equities MSTR, COIN, MARA, RIOT, HUT, HIVE.

$MSTR $COIN $MARA $RIOT $HUT $HIVE tomorrow morning should see a STRONG GAP UP  imo  🔥  🚀
#SupDup


industry='Financial Data & Stock Exchanges'


Summary: Accumulating INTC on dips, agreeing with $30 price target thesis for near and long term.

@Mr_Derivatives I agree, I am accumulating on dips for NT & LT imo.

I still believe $INTC is a $30 name.

Gotta be ultra patient with this one.


Summary: Long SMCI to $50–$100 within 2–3 years from current ~$30 level.

$SMCI $30++++ rn, Remember what I had said  👇  🤑
It will be back to $50 - $100 within 2-3 years imo
#SupDup

https://t.co/RllcQqJ0aG

$SMCI <$23 = GOLDEN BUYING OPPORTUNITY for investors with 2-3 yrs patience and heavy risk tolerance imo.
#SupDup


Summary: Bullish on ALLR despite recent decline; expects a recovery.

@DanjeTG Not happy with the decline but Patience, It will have its day imo


Summary: Loading up long RR below $0.88, targets $1–$7 in 2025.

$RR <$0.88 - I am LOADING UP building a large long position because I see it at between $1 - $7 in 2025
Join me if you like it but only if you have some patience.
Remember penny flippers only made pennies in $LAES $WKEY $RKLB $LUNR $AAOI $GNPX $LUNRW and some other long stock picks of mine but real jackpot winners were investors with little more patience. Those hit   💰  given stocks went up between 300% to 1000% recently that too quickly imo
#SupDup